Taking into account the deleterious effect of metastases on the survival of breast cancer patients, our data could heighten the interest in evaluating the abundance of the CAF-S1 FAP+ subpopulation, in vivo, in a non-invasive manner, by means of [99mTc]Tc-iFAP SPECT in axillary LNm during the initial clinical approach (staging) to determine the prognosis and the benefit of therapies, such as anti-FAP, anti-TGFβ, anti-CXCR4, and/or anti-PD-L1 immunotherapy, in combination with standard therapies (Figure 8). Here, TGFB1 is linked to breast cancer.